TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$50 Million


At-the-market Offering

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.